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Background: Hypertension and dyslipidemia are often insufficiently controlled in persons with type 2 diabetes
(T2D) in Germany. In the current study we evaluated individual characteristics that are assumed to influence the
adequate treatment and control of hypertension and dyslipidemia and aimed to identify the patient group with
the most urgent need for improved health care.
Methods: The analysis was based on the DIAB-CORE project in which cross-sectional data from five regional
population-based studies and one nationwide German study, conducted between 1997 and 2006, were pooled.
We compared the frequencies of socio-economic and lifestyle factors along with comorbidities in hypertensive
participants with or without the blood pressure target of < 140/90 mmHg. Similar studies were also performed
in participants with dyslipidemia with and without the target of total cholesterol/HDL cholesterol ratio < 5.
Furthermore, we compared participants who received antihypertensive/lipid lowering treatment with those who
were untreated. Univariable and multivariable logistic regression models were used to assess the odds of potentially
influential factors.
Results: We included 1287 participants with T2D of whom n= 1048 had hypertension and n = 636 had
dyslipidemia. Uncontrolled blood pressure was associated with male sex, low body mass index (BMI), no history of
myocardial infarction (MI) and study site. Uncontrolled blood lipid levels were associated with male sex, no history
of MI and study site. The odds of receiving no pharmacotherapy for hypertension were significantly greater in men,
younger participants, those with BMI < 30 kg/m2 and those without previous MI or stroke. Participants with
dyslipidemia received lipid lowering medication less frequently if they were male and had not previously had
an MI. The more recent studies HNR and CARLA had the greatest numbers of well controlled and treated
participants.
Conclusion: In the DIAB-CORE study, the patient group with the greatest odds of uncontrolled co-morbidities and
no pharmacotherapy was more likely comprised of younger men with low BMI and no history of cardiovascular
disease.
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Background
Hypertension and dyslipidemia constitute major public
health problems as they increase the risk of cardiovascu-
lar diseases (CVDs), especially in patients with concomi-
tant type 2 diabetes (T2D) [1-4].
Nevertheless, several epidemiological studies indicate
disappointing deficiencies in the detection and adequate
treatment of hypertension and dyslipidemia in Germany
with minimal improvement over the last decades [5-13].
About ten years ago, the South German site of the
Monitoring Trends and Determinants in Cardiovascular
Disease (MONICA) Study, the forerunner to the Co-
operative Health Research in the Region of Augsburg
(KORA) Study, revealed that the proportion of hyperten-
sive participants with controlled hypertension < 140/
90 mmHg was only 7% in men and 13% in women [6].
An earlier analysis of regional differences using data of
the two population-based German studies KORA and
SHIP (Study of Health in Pomerania) with participants
aged 25-74 years found that of all hypertensive partici-
pants, 8.4% in SHIP and 10.2% in KORA, were treated
and well controlled. Recently, data of the German
DIAB-CORE cooperation revealed that 64% of all parti-
cipants with T2D and 49% of participants without T2D,
aged 45-74 years, had untreated or insufficiently treated
hypertension [8]. Despite the increased awareness of
physicians and the public regarding the beneficial effects
of blood pressure control on cardiovascular outcomes
such as myocardial infarction and stroke ([5]), the data
suggest that further barriers must exist that hinder opti-
mal health care delivery.Table 1 Studies included in the pooled DIAB-CORE sample (45




DHSb West Germany 2003–2004
(Dortmund)
CARLAc East Germany 2002–2006
(Halle)
HNR d West Germany (Bochum, Essen,
Mülheim an der Ruhr)
2000–2003




aSHIP: Study of Health in Pomerania; bDHS: Dortmund Health Study; cCARLA: Cardio
eKORA (Survey S4): Cooperative Health Research in the Region of Augsburg; fGNHIE
BP > = 140/90 mmHg or using anti-hypertensive medication.
TC/HDL >= 5 or using lipid-lowering medication.Objectives
To our knowledge, no population-based study in Germany
has so far dealt with characteristics of patients with T2D
and hypertension and/or dyslipidemia who are not suffi-
ciently treated for these serious conditions. In our study,
we describe demographic, socio-economic and lifestyle
factors in DIAB-CORE participants with diabetes and con-
comitant hypertension or dyslipidemia and analyse the fac-
tors associated with insufficient disease control and absent
pharmacotherapy. We therefore aim to identify the group
of patients with the most urgent need for intensified care.Methods
Study design and setting
The DIAB-CORE Consortium consists of the following
population-based studies (from north to south): the
Study of Health in Pomerania (SHIP, Greifswald), the
Dortmund Health Study (DHS, Dortmund), the Cardio-
vascular Disease, Living and Ageing (CARLA, Halle
(Saale)) Study, the Heinz Nixdorf-Recall (HNR, Risk Fac-
tors, Evaluation of Coronary Calcification, and Lifestyle,
Bochum, Essen, Mülheim a. d. Ruhr) Study, the Co-
operative Health Research in the Region of Augsburg
(KORA, Augsburg) Study, and the nationwide German
National Health Interview and Examination Survey 1998
(GNHIES98), see Table 1.
All studies were conducted between 1997 and 2006
and used similar instruments, questionnaires and med-
ical measurements to assess data. Detailed descriptions
of study designs, samples and procedures are available
elsewhere [14-20]. Ethical approval was obtained for–74 years)
N (%) Age (years) Hypertension Dyslipidemia
mean (SD) N (%) N (%)
251 (19.5) 62.8 (7.5) 215 (85.7) 143 (57.0)
87 (6.8) 64.1 (8.0) 73 (83.9) -
174 (13.5) 63.5 (7.3) 155 (89.6) 84 (48.6)
350 (27.2) 63.0 (7.2) 263 (78.5) 174 (52.1)
146 (11.3) 63.3 (6.7) 114 (78.6) 80 (55.9)
279 (21.7) 62.7 (6.8) 228 (81.7) 155 (59.6)
1287 63.1 (7.2) 1048 (82.5) 636 (54.8)
vascular Disease, Living and Ageing in Halle; d HNR: Heinz Nixdorf-Recall;
S98: German National Health Interview and Examination Survey 1998.
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and frequencies compared.Variables
Age
Participants were classified in five age groups using five
year intervals.Type 2 diabetes
T2D was defined based on self-report or self-reported
intake of oral anti-diabetic agents, insulin or a combin-
ation of both. Some studies lacked information on dia-
betes type. Thus, in order to exclude participants who
probably had Type 1 diabetes, self-reported age at diag-
nosis of diabetes was used, and only those patients with
an age at diagnosis of > 30 years were included in the
T2D group.Hypertension
Hypertension was defined using the mean of the second
and third blood pressure measurements (the first and
second measurements in DHS) conducted at the study
centres with systolic blood pressure ≥140 and/or dia-
stolic blood pressure ≥90 mmHg, or intake of anti-
hypertensive medication in participants with physician’s
diagnosis of hypertension (“awareness”). Participants
with hypertension were categorized into one of the fol-
lowing four subgroups: (1) aware (with physician’ diag-
nosis) and controlled treated to target levels of < 140/
90 mmHg, (2) aware and treated, but not reaching target
blood pressure values of < 140/90 mmHg, i.e. uncon-
trolled treated, (3) aware, but not treated, (4) unaware of
hypertension. Thus, “awareness” of hypertension applied
to participants in categories 1, 2 and 3, “treatment” ap-
plied to those in categories 1 and 2 and “control” to
those in category 1.Dyslipidemia
Total cholesterol, high-density lipoprotein (HDL) chol-
esterol and low-density lipoprotein (LDL) cholesterol
levels were measured from random blood samples. Dys-
lipidemia was defined analogously to hypertension using
information on lipid-lowering medication intake, self-
reported information on physician's diagnosis and a total
cholesterol to HDL cholesterol ratio (TC/HDL) of > = 5
[21,22].Myocardial infarction (MI) and stroke
Self-reported data on myocardial infarction and stroke
(“Did you ever have a myocardial infarction/stroke, diag-
nosed by a physician?”) was assessed identically in all
studies.Anti-hypertensive medication
All study participants were asked to bring original pack-
aging of their medications used during the last seven
days to the examination. The variable “anti-hypertensive
medication” included any prescription of medication
belonging to the ATC subgroups C02 (antihyperten-
sives), C03 (diuretics), C04 (peripheral vasodilators), C07
(beta blocking agents), C08 (calcium channel blockers)
and C09 (agents reacting on the renin-angiotensin
system).
Lipid-lowering medication
Medications of the ATC subgroup C10 (lipid modifying
agents) were included in the variable “lipid-lowering
medication”.
Body mass index (BMI)
The BMI (kg/m2) was calculated using standardized
weight and height measurements.
Smoking
Two categories (current vs. ex- and never smoker) were
defined to differentiate risk types. A current smoker
reported smoking at least one cigarette per day. Persons
who had reported that they had smoked at least one
cigarette per day in the past but who quit smoking at
least one year ago were defined as ex-smokers. Never-
smokers were defined as those persons who had never
smoked or smoked only occasionally (< 1 cigarette day).
Physical inactivity
In all studies, physical activity was assessed by self-report
only. A threshold of less than 1 h of physical activity per
week was determined for a high risk lifestyle. Assessment
of activity was restricted to all kinds of exercise training
but did not comprise low level exercise such as stepping
stairs or walking, as this type of exercise was not assessed
in all studies.
Educational level
In all studies, the participants were asked for their high-
est level of school qualification obtained. We classified
educational level as a dichotomous variable contrasting
low with medium or high level. According to the German
school system, low educational level includes participants
with up to 9 years of schooling. Medium educational
level is equivalent to 10 years of schooling and high edu-
cational level to 12 or 13 years of schooling, which is
required to enter a university.
Income
Information on monthly net household income as well
as on household size was obtained from interviews. As
the ages of household members were not available
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culate the equivalent income according to the OECD
equivalence scale. That is why the equivalent income
was calculated according to the Luxembourg Income
Study (income/household size) [23]. Pooling of income
data was conducted by a regional approach, calculating
the median income for each of the study centers separ-
ately. This approach allowed us to take into account
overall income differences between the regions. For each
study, we differentiated three income groups (<60% of
the study-specific median income, ≥60% up to 150%,
>150%) and pooled these groups across the six studies.
Participants
The pooled data set included 1,287 participants with
T2D aged 45 to 74 years. In the nationwide survey
GNHIES98, 3% non-German citizens were included,
KORA, SHIP and CARLA focused on participants of
German nationality, and the other studies collected in-
formation on birthplace only. Two-stage cluster sam-
pling or stratified random sampling were used. Overall
response ranged between 56 and 69%.
The hypertension sub-analysis included 1,048 hyper-
tensive participants. N= 17 participants were excluded
due to missing information on: study blood pressure
measurement (n = 3), physician’s diagnosis of hyperten-
sion (n = 3), and/or medication intake (n = 14).
The dyslipidemia sub-analysis included 636 partici-
pants with dyslipidemia according to the definition spe-
cified above. N = 126 participants had to be excluded
due to missing information on laboratory measurements
(n = 32), physician’s diagnosis of dyslipidemia (n = 90, all
participants of DHS and 3 of HNR), and/or medication
intake (n = 14). N= 16 participants were not included in
either one of the two sub-analyses.
Statistical analyses
T2D participants with hypertension, with or without the
blood pressure target of < 140/90 mmHg, and T2D parti-
cipants with dyslipidemia with or without the target of
total cholesterol/HDL cholesterol < 5, as well as T2D
participants with or without treatment were compared
with respect to their lifestyle factors, cardiovascular bur-
den, clinical measurements and medications. Continuous
variables were characterized by means and standard
deviations (SD), categorical variables were described as
percentages. Differences between groups were calculated
using t-tests and Wilcoxon tests (continuous variables)
or chi-square tests and univariable logistic regression
models (categorical variables). At first, univariable logis-
tic regression models were programmed to identify fac-
tors associated with blood pressure, lipid ratio or
medication intake. In a second step, variables found to
be significantly associated with the respective outcomewere included in multivariable models to examine
adjusted effects.
The goodness-of-fit of adjusted models was assessed
by the c-value, and the Hosmer-Lemeshow test. The
c-value describes the area under the ROC-curve, ranging
from 0.5 (random correlations) to 1.0 (perfect fit). In
epidemiologic studies, values between 0.6 and 0.8 are
usually regarded as satisfactory. The Hosmer-Lemeshow
test compares observed and predicted values with each
other. If there is no significant difference (at the signifi-
cance level of 0.05) the model is characterized as being
appropriate.
A two-sided alpha level of 0.05 was chosen as criterion
for statistical significance. All analyses were carried out




Of 1,287 T2D participants aged 45-74 years, n = 1,048
(82.5%) had hypertension and n= 636 (54.8%) had dysli-
pidemia. N = 530 (41.2%) had both conditions and were
included in both sub-analyses.
The frequency of hypertension in persons with T2D
differed slightly between studies, ranging from 78.5% in
HNR to 89.6% in CARLA. Likewise, the number of parti-
cipants with dyslipidemia ranged from 48.6% in CARLA
to 59.6% in GNHIES98. The mean age was 63.1 years
(Std. 7.2 years), and was very similar across all studies
(Table 1). In total, 45.1% of participants were female, ran-
ging from 40.0% in HNR to 49.8% in GNHIES98. Within
the group of hypertensive participants, 46.3% were
female, among participants with dyslipidemia, 43.1%
were female.
Descriptive data
Of 1,048 participants with T2D and hypertension,
n = 240 (22.9%) had controlled blood pressure of < 140/
90 mmHg, and n = 808 (77.1%) were uncontrolled. Dysli-
pidemia was treated to TC/HDL ratio < 5 in 143 (22.5%)
of 636 T2D participants and uncontrolled dyslipidemia
was observed in 493 (77.5%) T2D participants (Figure 1).
Frequencies of associated variables, stratified by parti-
cipants with and without controlled hypertension and
with and without controlled dyslipidemia, respectively,
are shown in Table 2. Frequencies of participant charac-
teristics, stratified by those treated for hypertension or
dyslipidemia, respectively, and those not treated for
these diseases are shown in Table 3.
Focus on differences between women and men
Systolic blood pressure (SBP) increased with age in par-
ticipants with T2D, while diastolic blood pressure (DBP)
decreased. Both measurements were consistently lower
Figure 1 Frequencies of controlled and uncontrolled hypertension and dyslipidemia.
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parts (mean SBP in women: 149.8 mmHg (SD 20.8) vs.
154.4 mmHg (20.6) in men, mean DBP 83.2 (11.1) and
86.6 (11.2) in women and men, respectively) (Figure 2).
Whilst men were more often free from hypertension
(19.3% vs. 15.2%), women were significantly more often
diagnosed and well controlled if affected: 25.0% of all
women had controlled hypertension, compared to 13.9%
in men, 43.5% were treated but did not achieve goal
levels (compared to 38.8% in men), 5.9% were not trea-
ted even though they had a physician’s diagnosis of
hypertension (compared to 7.3% in men), and 10.3% had
unknown hypertension (compared to 20.6% in men)
(see Figure 3).
Total cholesterol and HDL-cholesterol were higher in
women than in men (232.2 mg/dl (SD 48.8) vs. 216.4 mg/dl
(48.0) and 53.9 (16.6) vs. 46.3 (14.0)) – albeit, 48.7% of
women and 35.1% of men had less than 50 or less than
40 mg/dl HDL respectively. However, the TC/HDL ratio
was lower in women (4.7 (1.7) vs. 5.0 (1.7)).
More women than men were not affected with dyslipi-
demia as defined by a TC/HDL ratio < 5 (47.5% vs.
43.4%), 14.9% were treated and well-controlled (vs. 10.2%
in men), 7.9% were treated but did not reach goal values
(compared to 6.7% in men), 16.3% were not treated des-
pite of a physician’s diagnosis (compared to 17.8% in
men) and 13.4% had unknown dyslipidemia (compared
to 21.9% in men) (see Figure 3).Factors associated with uncontrolled hypertension or
uncontrolled dyslipidemia
Univariable logistic regression models yielded significant
associations of uncontrolled hypertension with sex (OR
for men: 2.01, 95% CI 1.50-2.69), BMI < 30 (OR=1.89,
95% CI 1.40-2.55), and study. Age in five groups was not
significantly associated but displayed a steady tendency
towards having the greatest odds in the second oldestgroup (65-69 years) compared to the youngest group
(45-54 years). With GNHIES98 as the reference study,
HNR had the smallest odds of uncontrolled hyperten-
sion (OR= 0.32, 95% CI 0.20-0.50), followed by CARLA
(OR= 0.47, 95% CI 0.28-0.79) and KORA (OR=0.52,
95% CI 0.30-0.91). Multivariable analysis with these sig-
nificant variables (i.e. sex, BMI and study) showed con-
sistent results as well as the associated factor ‘no
previous MI’ which reached statistical significance (OR=
1.70, 95% CI 1.06-2.70). A model including only sex,
BMI and study had a c-value of 0.68 and a non-
significant Hosmer-Lemeshow test (p = 0.78).
Uncontrolled dyslipidemia was significantly associated
with sex (OR for men: 1.82, 95% CI 1.25-2.65), no pre-
vious MI (OR= 2.22, 95% CI 1.37-3.59) and study (OR
for CARLA: 0.24, 95% CI 0.13-0.46 and HNR 0.41,
95% CI 0.23-0.74, GNHIES98 as reference). Again, age
was not significantly associated, but showed some ten-
dency, albeit in the other direction, with the youngest
age group displaying the greatest odds of uncontrolled
dyslipidemia (70-74 years as reference). Multivariable
analysis with sex, MI, and study generated consistent
odds. A model including only these variables had a
c-value of 0.69 and a non-significant Hosmer-Leme-
show test result (p = 0.96). Smoking, physical activity,
educational level and income were not significantly
associated with either control of hypertension or dysli-
pidemia (Table 4).Factors associated with no pharmacotherapy for
hypertension or dyslipidemia
Using univariable regression models, we found signifi-
cant odds of non-use of anti-hypertensive medication in
younger study participants (OR for 45-54 years: 2.54,
95% CI 1.54-4.20, OR for 55-59 years: 2.15, 95% CI
1.31-3.53, 70-74 years as reference), males (OR= 2.11,
95% CI 1.54-2.87), current smokers (OR: 1.80, 95% CI




> = 140/90 mmHg
Controlled dyslipidemia
TC/HDL ratio < 5
Uncontrolled dyslipidemia
TC/HDL ratio >=5
n=240 n=808 n=143 n=493
Age (years) 62.8 (7.2) 63.8 (6.9) 63.8 (6.7) 62.4 (7.3)
Women (%) 59.6 42.3 54.6 39.8
BMI (kg/m2) 32.4 (5.9) 30.7 (5.0) 30.6 (5.1) 31.2 (5.2)
BMI > = 30 kg/m2 (%) 64.2 48.6 51.1 50.7
Current smoking (%) 15.7 14.2 13.4 19.9
Low physical activity (%) 71.2 73.5 68.1 75.0
Low income (%) 17.8 17.0 17.4 18.5
Low education (%) 78.3 78.7 80.9 79.6
Diabetes duration (years) 8.3 (7.7) 8.9 (7.5) 10.1 (7.9) 7.9 (7.0)
Diabetes treatment (%)
Diet only or no treatment (%) 20.0 21.9 20.3 21.5
OAD only (%) 47.5 51.2 42.7 53.7
Insulin only (%) 19.6 17.1 19.6 13.4
OAD and Insulin (%) 12.9 9.8 17.5 11.4
Blood pressure (mm Hg)
Systolic BP (mm Hg) 126.3 (10.4) 160.0 (16.4) 148.1 (23.9) 147.6 (21.6)
Diastolic BP (mm Hg) 75.7 (7.9) 87.8 (10.7) 80.6 (11.1) 84.1 (11.4)
Hypertension (%) 100.0 100.0 85.9 82.8
current BP > =140/90 (%) 0.0 100.0 59.9 65.9
Cholesterol (mg/dl)
TC (mg/dl) 218.4 (46.2) 226.8 (50.3) 199.0 (37.0) 244.5 (53.6)
LDL (mg/dl) 132.3 (37.9) 138.5 (39.9) 114.4 (32.4) 153.9 (42.1)
HDL (mg/dl) 50.2 (15.7) 50.0 (16.0) 56.3 (15.5) 39.1 (8.4)
Dyslipidemia (%) 53.8 55.9 100.0 100.0
current TC/HDL ratio >= 5 (%) 37.1 43.0 0.0 100.0
Myocardial infarction (%) 13.4 9.4 22.7 11.7
Stroke (%) 9.2 7.4 7.0 7.7
Numbers are means (SD) or percentages and relate to the number of subjects available for analysis.
BMI: body mass index, OAD: oral anti-diabetic medication, TC: total cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, CVD: cardiovascular
disease, BP: blood pressure.
BP >=140/90 mmHg or using anti-hypertensive medication.
TC/HDL ratio > =5 or using lipid-lowering medication.
Test of the difference between participants with controlled hypertension and those with uncontrolled hypertension, p <0.05.
Test of the difference between participants with controlled dyslipidemia and those with uncontrolled dyslipidemia, p <0.05.
Rückert et al. Cardiovascular Diabetology 2012, 11:120 Page 6 of 15
http://www.cardiab.com/content/11/1/1201.22-2.64) and participants with BMI < 30 (OR= 2.06,
95% CI 1.52-2.79). Moreover, no previous MI (OR= 3.75,
95% CI 1.79-7.82), no previous stroke (OR= 3.12, 95%
CI 1.42-6.88) and study (OR for CARLA: 0.42, 95% CI
0.24-0.71, OR for HNR: 0.60, 95% CI 0.40-0.92,
GNHIES98 as reference) were significantly associated
with untreated hypertension. In multivariable models
adjusted for age, sex, BMI, MI, stroke, and study, the
odds remained significant, except for smoking. A model
including only these significant variables was character-
ized by a c-value of 0.71 and a non-significant Hosmer-
Lemeshow test result (p = 0.46).Non-use of lipid lowering medication in participants
with dyslipidemia was univariably associated with male
sex (OR=1.75, 95% CI 1.27-2.43) and no MI (OR=3.16,
95% CI 1.99-5.01). Multivariable analysis adjusted for
these two variables yielded additionally significant odds
for no concomitant hypertension (OR=1.71, 95% CI 1.06-
2.78), physical inactivity (OR=1.49, 95% CI 1.03-2.17) and
the CARLA study (OR=0.56, 95% CI 0.32-0.98). A model
including only sex and MI had a c-value of 0.64 and a
non-significant Hosmer-Lemeshow test (p= 0.62). Neither
education nor income were associated with treatment of
hypertension or dyslipidemia (Table 5).









n= 822 n= 226 n=240 n=396
Age (years) 64.1 (6.8) 61.8 (7.3) 63.5 (6.5) 62.2 (7.5)
Women (%) 50.1 32.3 51.7 37.9
BMI (kg/m2) 31.5 (5.4) 29.5 (4.2) 30.8 (5.1) 31.2 (5.2)
BMI >= 30 kg/m2 (%) 56.0 38.2 51.3 50.5
Current smoking (%) 12.8 20.9 14.8 20.6
Low physical activity (%) 73.4 71.4 69.1 76.0
Low income (%) 16.8 18.4 18.3 18.2
Low education (%) 79.4 75.7 81.3 79.0
Diabetes duration (years) 9.0 (7.6) 7.8 (7.0) 9.2 (7.3) 7.9 (7.2)
Diabetes treatment (%)
Diet only or no treatment (%) 19.6 28.3 18.3 23.0
OAD only (%) 49.5 53.5 46.3 54.2
Insulin only (%) 19.1 12.4 19.6 11.9
OAD and Insulin (%) 11.8 5.8 15.8 10.9
Blood pressure (mm Hg)
Systolic BP (mm Hg) 150.4 (21.6) 159.0 (16.0) 147.3 (23.3) 148.0 (21.4)
Diastolic BP (mm Hg) 83.7 (11.3) 90.0 (9.7) 80.9 (11.2) 84.8 (11.4)
Hypertension (%) 100 100 87.0 81.3




TC (mg/dl) 224.9 (51.2) 224.6 (43.0) 215.6 (50.2) 245.5 (52.8)
LDL (mg/dl) 136.8 (40.1) 138.0 (37.2) 126.9 (42.3) 155.3 (40.5)
HDL (mg/dl) 49.9 (15.8) 50.3 (16.3) 48.8 (15.8) 39.4 (8.5)
Dyslipidemia (%) 56.1 52.9 100 100
current TC/HDL ratio >= 5 (%) 40.9 44.6 40.4 100 (due to definition
of dyslipidemia)
Myocardial infarction (%) 12.1 3.6 23.1 8.7
Stroke (%) 9.1 3.1 8.0 7.3
Numbers are means (SD) or percentages and relate to the number of subjects available for analysis.
BMI: body mass index, OAD: oral anti-diabetic medication, TC: total cholesterol, LDL: low-density lipoprotein, HDL: high-density lipoprotein, CVD: cardiovascular
disease, BP: blood pressure.
BP >=140/90 mmHg or using anti-hypertensive medication.
TC/HDL ratio > =5 or using lipid-lowering medication.
Test of the difference between participants with antihypertensive medication and those without such medication, p <0.05.
Test of the difference between participants with lipid lowering medication and those without such medication, p <0.05.
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Key results
Uncontrolled blood pressure in T2D participants with
(diagnosed or unrecognized) hypertension was associated
with male sex, BMI < 30 kg/m2, no previous MI, and study
site. Similarly, uncontrolled blood lipid levels in T2D par-
ticipants with dyslipidemia (diagnosed or unrecognized)
were more frequent in men, those who had not suffered
MI and attendees of the older DIAB-CORE studies.
Lack of treatment for hypertension was related to
younger age, male sex, smoking, BMI < 30, no history ofMI or stroke, and study site. Male T2D participants
without concomitant hypertension and who had not suf-
fered MI had significantly greater odds of untreated dys-
lipidemia than other participants in DIAB-CORE.
Socioeconomic features such as educational level and
income were not significantly associated with either dis-
ease control or pharmacotherapy; lifestyle factors were
only associated in some models.
On the one hand, the results of our analyses indicate
that the vast majority of patients with T2D in Germany
are not adequately treated for hypertension and/or
Figure 2 Systolic and diastolic blood pressure in all women and men with T2D stratified by age groups.
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found to considerably increase the risk of co-morbidities
and complications such as MI, stroke, nephropathy and
retinopathy.
On the other hand, we confirmed the presumption
that patients with additional risk factors, such as
advanced age, previous MI, previous stroke or obesity
are treated more often for hypertension and dyslipidemia
and (apart from those with older age) more frequently
achieve adequate blood pressure and lipid target levels.
The difference between female and male participants
was pronounced and consistent over all sub-analyses.
Strengths and limitations
The essential strength of our study is the large
population-based sample drawn from the general German
population, aged 45 to 74 years, and the fact that both,
laboratory measurements and information on medication
intake were available.Differences in the frequencies of hypertension and dysli-
pidemia between studies were probably due to the rela-
tively small numbers of affected participants within the
individual studies and analyses. Due to the pooling
process, only similarly collected and coded data of all six
studies could be used and the least common denominator
had to be found. Therefore, the definition of diabetes was
based on self-report of physician’s diagnosis and treatment
with anti-diabetic agents rather than on clinical diagnosis
and medical records. Blood pressure was calculated using
the mean of the second and third measurements in all
studies except for DHS, where only two measurements
were performed and used to calculate the mean.
Moreover, measurements of blood pressure and lipids
based on a single testing opportunity provide evidence
for the respective condition, but are not equal to a clin-
ical diagnosis with repeated measurements. We cannot
exclude cases of ‘white coat hypertension’, i.e. elevated
blood pressure caused by the excitement of the
unfamiliar situation.
Figure 3 Percentages of all participants with T2D - without hypertension or without dyslipidemia, with controlled, uncontrolled
treated, known, but not treated, and unrecognized disease status stratified by sex.
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http://www.cardiab.com/content/11/1/120Due to compliance issues, women might have reported
their medication intake more reliably than men, thus
pharmacotherapy in men could have been underesti-
mated and consequently, sex-specific differences overes-
timated in these analyses.
Generalization
Patient-centered studies in Germany and other countries
have so far examined awareness, treatment, control and
factors associated with insufficient control of co-
morbidities in patients with and without diabetes. A sys-
tematic review by McLean et al. from 2008, which
included 26 studies from different countries with 66,833
diabetes patients with co-morbid hypertension, con-
cluded that 83% (range 32-100%) of patients were trea-
ted, yet only about 29% (range 5-59%) had their blood
pressure controlled to < 140/90 mmHg. The proportions
of treatment to control were similar and thus equally in-
sufficient between studies and countries. Unfortunately,
the authors did not report person-related factors asso-
ciated with disease control [24].Differences by gender
There are very few studies that have reported factors asso-
ciated with cardiovascular disease control in patients with
diabetes, as opposed to adults in general, irrespective of
diabetes status. However, a number of recent studies that
focused on gender differences [25-30] found that female
patients with diabetes had a worse cardiovascular risk pro-
file and were less controlled compared to their male coun-
terparts. Our study confirmed these results in part;
women in DIAB-CORE had higher total cholesterol values
than men. However, since HDL-cholesterol values were
also higher, the TC/HDL ratio was lower and thus more
beneficial in women. In all studies [25-30], blood pressure
was higher in women, especially in patients with cardio-
vascular disease. Although this sex difference was abro-
gated in some analyses after adjustment for associated
variables [27,28]. There was either no sex difference in the
amount of antihypertensive and lipid-lowering medica-
tion, or women took more medication, which is in agree-
ment with our study. Furthermore, our results indicate
that men are about twice as often unaware of their hyper-
tension and dyslipidemia as women, which is well in line
Table 4 Factors associated with high BP* and cholesterol^ in diabetic study participants with concomitant (diagnosed
or unrecognized) hypertension or dyslipidemia
Hypertension Dyslipidemia
N BP > =140/90 Unadjusted Adjusted for Sex,
BMI, Study
N TC/HDL ratio > = 5 Unadjusted Adjusted for Sex,
MI, Studyn (%) n (%)
1048 808 (77.1) OR (95%CI) OR (95%CI) 636 493 (77.5) OR (95%CI) OR (95%CI)
Age in years
70-74 257 202 (78.6) 1.45 (0.90-2.35) 1.48 (0.90-2.46) 134 101 (75.4) Reference Reference
65-69 252 201 (79.8) 1.56 (0.96-2.54) 1.70 (1.02-2.84) 146 105 (71.9) 0.84 (0.49-1.43) 0.83 (0.47-1.45)
60-64 254 196 (77.2) 1.34 (0.83-2.15) 1.33 (0.81-2.19) 157 126 (80.3) 1.33 (0.76-2.32) 1.28 (0.71-2.30)
55-59 151 113 (74.8) 1.18 (0.70-1.99) 1.13 (0.65-1.96) 98 79 (80.6) 1.36 (0.72-2.57) 1.23 (0.63-2.40)
45-54 134 96 (71.6) Reference Reference 101 82 (81.2) 1.41 (0.75-2.66) 1.33 (0.70-2.59)
Sex
Male 563 466 (82.8) 2.01 (1.50-2.69) 2.00 (1.47-2.72) 362 297 (82.0) 1.82 (1.25-2.65) 2.23 (1.49-3.33)
Female 485 342 (70.5) Reference Reference 274 196 (71.5) Reference Reference
BMI
>= 30 546 392 (71.8) Reference Reference 322 249 (77.3) Reference Reference
<30 500 414 (82.8) 1.89 (1.40-2.55) 1.75 (1.28-2.40) 312 242 (77.6) 1.01 (0.70-1.47) 0.82 (0.55-1.23)
Currently smoking
Yes 150 113 (75.3) Reference Reference 115 96 (83.5) 1.61 (0.94-2.74) 1.56 (0.88-2.75)
No 880 682 (77.5) 1.13 (0.75-1.69) 1.30 (0.84-1.99) 510 387 (75.9) Reference Reference
Physical inactivity
Yes 757 589 (77.8) 1.13 (0.82-1.55) 0.98 (0.70-1.38) 461 365 (79.2) 1.40 (0.93-2.11) 1.27 (0.82-1.98)
No 280 212 (75.7) Reference Reference 167 122 (73.1) Reference Reference
School education
Low 811 627 (77.3) 1.02 (0.72-1.46) 1.07 (0.73-1.55) 499 385 (77.2) Reference Reference
High and middle 221 170 (76.9) Reference Reference 126 99 (78.6) 1.09 (0.68-1.74) 1.00 (0.60-1.64)
Income
Low 162 124 (76.5) Reference Reference 104 81 (77.9) Reference Reference
Middle 674 521 (77.3) 1.04 (0.70-1.57) 0.86 (0.56-1.33) 405 306 (75.6) 0.88 (0.52-1.47) 0.84 (0.49-1.45)
High 109 86 (78.9) 1.15 (0.64-2.06) 0.98 (0.53-1.83) 62 52 (83.9) 1.48 (0.65-3.35) 1.12 (0.47-2.65)
Myocardial infarction
Yes 107 75 (70.1) Reference Reference 89 57 (64.0) Reference Reference
No 934 727 (77.8) 1.50 (0.96-2.33) 1.70 (1.06-2.70) 540 431 (79.8) 2.22 (1.37-3.59) 2.81 (1.69-4.69)
Stroke
Yes 81 59 (72.8) Reference Reference 48 38 (79.2) 1.11 (0.54-2.28) 1.19 (0.56-2.55)
No 960 742 (77.3) 1.27 (0.76-2.12) 1.63 (0.95-2.79) 585 453 (77.4) Reference Reference
Dyslipidemia Hypertension
Yes 530 410 (77.4) 1.09 (0.81-1.47) 1.01 (0.73-1.38) 530 408 (77.0) Reference Reference
No 426 323 (75.8) Reference Reference 105 85 (81.0) 1.27 (0.75-2.15) 1.32 (0.75-2.31)
Study
GNHIES98 228 195 (85.5) Reference Reference 155 135 (87.1) Reference Reference
CARLA 155 114 (73.6) 0.47 (0.28-0.79) 0.49 (0.29-0.83) 84 52 (61.9) 0.24 (0.13-0.46) 0.21 (0.11-0.40)
DHS 73 63 (86.3) 1.07 (0.50-2.29) 1.10 (0.51-2.39) - - - -
KORA 114 86 (75.4) 0.52 (0.30-0.91) 0.57 (0.32-1.02) 80 63 (78.8) 0.55 (0.27-1.12) 0.52 (0.25-1.07)
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Table 4 Factors associated with high BP* and cholesterol^ in diabetic study participants with concomitant (diagnosed
or unrecognized) hypertension or dyslipidemia (Continued)
HNR 263 172 (65.4) 0.32 (0.20-0.50) 0.30 (0.19-0.47) 174 128 (73.6) 0.41 (0.23-0.74) 0.38 (0.21-0.69)
SHIP 215 178 (82.8) 0.81 (0.49-1.36) 0.84 (0.50-1.41) 143 115 (80.4) 0.61 (0.33-1.14) 0.63 (0.33-1.20)
Uncontrolled hypertension – Sex, BMI, Study: ROC = 0.68, Hosmer-Lemeshow p-value = 0.78.
Uncontrolled dyslipidemia – Sex, MI, Study: ROC= 0.69, Hosmer-Lemeshow p-value = 0.96.
*BP >= 140/90 mm Hg.
^ ratio total cholesterol/HDL cholesterol > = 5.
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http://www.cardiab.com/content/11/1/120with known gender differences concerning health behav-
iour. Especially in the age group of about 30 to 60 years,
men use health care services less than women and tend to
undervalue health care and health behaviour [31,32]. Sev-
eral authors hypothesize that societally dominant ‘trad-
itional masculinity’ leads men to adopt beliefs and
behaviours that increase health risks and support the ideal
of the ‘bulletproof superhero’ who would be embarrassed
to check his cholesterol level [33-35].
Influence of age
Findings on the influence of age on hypertension control
are controversial (e.g. [36,37]). An explanation for less
control with simultaneously intensified treatment, as seen
in our study, might be that resistant hypertension occurs
more often in older persons [38]. Accordingly, this associ-
ation was not detected for dyslipidemia. A cross-sectional
study in Sweden examined the assumption that the excess
cardiovascular risk of persons with diabetes compared to
persons without diabetes decreases with increasing age.
However, the authors found that the burden of CVD risk
factors clustered over the entire life span with increasing
glucometabolic disturbance, especially in older women.
Likewise, self-rated health decreased with increasing
cardio-metabolic risk and age. The authors suggest that a
decreased burden of risk in older patients with diabetes
might be due to a survival bias [39].
Association with body mass index
In our study obese participants (BMI ≥ 30 kg/m2)
received medication more frequently and were more
often well treated for hypertension, although they were
more often affected with hypertension than leaner indi-
viduals (data not shown). A Swedish population-based
study in hypertensive 60-year-old persons with and with-
out diabetes by Carlsson et al. found an inverse, direct
association of high waist circumference with uncon-
trolled hypertension [40]. The same seems to be true for
patients in primary care irrespective of diabetes status
[41]. Bramlage et al. found that the odds of good blood
pressure control in diagnosed and treated individuals
was significantly smaller in overweight and obese pri-
mary care patients than in patients with normal weight.
Using data of physician diagnosed hypertensive DIAB-
CORE participants without diabetes (n = 5012), we foundthat 29.2% of those with BMI < 25 had controlled hyper-
tension (41.2% were uncontrolled and 29.6% untreated)
compared to 28.6% of those with BMI ≥ 30 (50.9% un-
controlled and 20.5% untreated). These results indicate
that obese people may be more difficult to treat and ob-
tain goal blood pressure than lean persons; however,
they appear to be more aware of their disease. The same
seems to be true for a comparison of hypertensive
people with and without T2D. Those with T2D are more
often treated and well-controlled, much more often trea-
ted but not controlled, half as often untreated and half
as often unrecognized, irrespective of BMI group (data
not shown) than those without T2D. All in all, obese
individuals do more often present with a blood pres-
sure ≥ 140/90 mmHg, irrespective of treatment. Thus,
people with additional risk factors (such as obesity and
diabetes) may be more aware of their blood pressure and
more often treated but at the same time, they are more
difficult to effectively treat.
Effect of socio-economic differences
We expected to find a significant negative association
of high socio-economic status with uncontrolled co-
morbidities, however no significant associations were
observed with any socio-economic characteristics and
the outcome variables. This might, in the case of school
education, be due to the unequal frequencies of low
(about 80%) vs. high and middle status, which owns to
the high mean age of the study population (63 years)
and the fact that older people mostly attended junior
high school only. In the previously mentioned Swedish
study, lack of health care due to low income was inde-
pendently associated with uncontrolled hypertension in
men (OR= 2.71, 95% CI 1.09-6.78) but not in women. In
contrast, living in an apartment instead of a house (as an
indicator of lower socio-economic status) remained a
significantly protective factor in an adjusted model in
women (OR= 0.55, 95%CI 0.35-0.85). The authors stated
that the finding was puzzling and offered no explanation
[40].
Association with previous cardiovascular disease
Carlsson et al. confirmed that previous cardiovascular
disease or coronary heart disease has a protective effect
on uncontrolled hypertension, probably because of more
Table 5 Factors associated with absent pharmacotherapy in diabetic study participants with concomitant (diagnosed













1048 226 (21.6) OR (95%CI) OR (95%CI) 636 396 (62.3) OR (95%CI) OR (95%CI)
Age in years
70-74 257 38 (14.8) Reference Reference 134 84 (62.7) Reference Reference
65-69 252 49 (19.4) 1.39 (0.87-2.21) 1.35 (0.83-2.19) 146 81 (55.5) 0.74 (0.46-1.20) 0.71 (0.43-1.16)
60-64 254 57 (22.4) 1.67 (1.06-2.62) 1.46 (0.90-2.35) 157 97 (61.8) 0.96 (0.60-1.55) 0.94 (0.57-1.54)
55-59 151 41 (27.2) 2.15 (1.31-3.53) 1.80 (1.06-3.05) 98 63 (64.3) 1.07 (0.62-1.84) 0.93 (0.53-1.63)
45-54 134 41 (30.6) 2.54 (1.54-4.20) 2.28 (1.34-3.90) 101 71 (70.3) 1.41 (0.81-2.45) 1.10 (0.62-1.95)
Sex
Male 563 153 (27.2) 2.11 (1.54-2.87) 2.11 (1.52-2.93) 362 246 (68.0) 1.75 (1.27-2.43) 2.02 (1.44-2.84)
Female 485 73 (15.1) Reference Reference 274 150 (54.7) Reference Reference
Smoking
Yes 150 46 (30.7) 1.80 (1.22-2.64) 1.40 (0.92-2.13) 115 80 (69.6) 1.49 (0.96-2.30) 1.30 (0.82-2.04)
No 880 174 (19.8) Reference Reference 510 309 (60.6) Reference Reference
BMI
>= 30 546 86 (15.8) Reference Reference 322 199 (61.8) Reference Reference
<30 500 139 (27.8) 2.06 (1.52-2.79) 1.98 (1.43-2.74) 312 195 (62.5) 1.03 (0.75-1.42) 0.89 (0.63-1.24)
Physical inactivity
Yes 757 160 (21.1) Reference Reference 461 298 (64.6) 1.42 (0.99-2.04) 1.49 (1.03-2.17)
No 280 64 (22.9) 1.11 (0.80-1.54) 1.10 (0.77-1.56) 167 94 (56.3) Reference Reference
School education
Low 811 168 (20.7) Reference Reference 499 308 (61.7) Reference Reference
High and middle 221 54 (24.4) 1.24 (0.87-1.76) 1.08 (0.74-1.58) 126 82 (65.1) 1.16 (0.77-1.74) 0.98 (0.64-1.50)
Income
Low 162 37 (22.8) Reference Reference 104 65 (62.5) Reference Reference
Middle 674 133 (19.7) 0.83 (0.55-1.26) 0.73 (0.47-1.14) 405 248 (61.2) 0.95 (0.61-1.48) 0.92 (0.58-1.47)
High 109 31 (28.4) 1.34 (0.77-2.34) 0.90 (0.49-1.65) 62 45 (72.6) 1.59 (0.80-3.15) 1.17 (0.57-2.39)
Myocardial infarction
Yes 107 8 (7.5) Reference Reference 89 34 (38.2) Reference Reference
No 934 217 (23.2) 3.75 (1.79-7.82) 3.65 (1.72 -7.75) 540 357 (66.1) 3.16 (1.99-5.01) 3.62 (2.25-5.82)
Stroke
Yes 81 7 (8.6) Reference Reference 48 29 (60.4) Reference Reference
No 960 219 (22.8) 3.12 (1.42-6.88) 3.45 (1.53-7.79) 585 366 (62.6) 1.10 (0.60-2.00) 0.99 (0.52-1.85)
Dyslipidemia Hypertension
Yes 530 109 (20.6) Reference Reference 530 322 (60.8) Reference Reference
No 426 97 (22.8) 1.14 (0.84-1.55) 1.15 (0.83-1.60) 105 74 (70.5) 1.54 (0.98-2.43) 1.71 (1.06-2.78)
Study
GNHIES98 228 65 (28.5) Reference Reference 155 102 (65.8) Reference Reference
CARLA 155 22 (14.2) 0.42 (0.24-0.71) 0.39 (0.22-0.69) 84 46 (54.8) 0.63 (0.37-1.08) 0.56 (0.32-0.98)
DHS 73 17 (23.3) 0.76 (0.41-1.41) 0.91 (0.47-1.74) - - - -
KORA 114 24 (21.1) 0.67 (0.39-1.14) 0.82 (0.46-1.45) 80 52 (65.0) 0.97 (0.55-1.70) 0.95 (0.53-1.72)
HNR 263 51 (19.4) 0.60 (0.40-0.92) 0.60 (0.39-0.93) 174 101 (58.1) 0.72 (0.46-1.13) 0.68 (0.42-1.08)
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Table 5 Factors associated with absent pharmacotherapy in diabetic study participants with concomitant (diagnosed
or unrecognized) hypertension or dyslipidemia (Continued)
SHIP 215 47 (21.9) 0.70 (0.46-1.08) 0.73 (0.46-1.16) 143 95 (66.4) 1.03 (0.64-1.66) 1.08 (0.65-1.79)
No pharmacotherapy for hypertension – Age, Sex, BMI, MI, Stroke, Study: ROC= 0.71, Hosmer-Lemeshow p-value = 0.46.
No pharmacotherapy for dyslipidemia – Sex, MI: ROC= 0.64, Hosmer-Lemeshow p-value = 0.62.
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symptom relief of angina pectoris [40].
Influence of more complex factors
There are a number of possible influences on uncon-
trolled hypertension and dyslipidemia that we could not
consider. For example, the Swedish study by Carlsson
et al. included data on nutrition and found that daily in-
take of fruit had an independent, protective effect in
men but not in women [40].
Steckelings, 2004 et al. [5] used data from primary care
patients, irrespective of diabetes status (the HYDRA
Study: Hypertension and Diabetes Screening and Aware-
ness Study), to describe possible determinants of unsatis-
factory hypertension control in Germany. Less than 30%
of treated and 19% of all patients, treated or untreated,
had controlled blood pressure <140/90 mmHg. The
frequency of diagnosis was particularly low in young
people, probably due to insufficient blood pressure
screening. The authors found that physicians used out-
dated guidelines and based treatment on diastolic pres-
sure. The great majority of participants (94%) stated that
they knew that hypertension is an important risk factor
for serious diseases, and most of them (63%) occasionally
measured their own blood pressure. However, the physi-
cians participating in the study often misclassified their
patients as ‘well controlled’ even though they had BP
measurements ≥ 140/90 mmHg.
According to a review by Düsing et al. 2006 [42], more
complex, hindering factors could also be insufficient
education and motivation provided to the patient by
physicians, patients’ reluctance to change lifestyle factors
or commence/modify drug treatment, lack of awareness
of the risks associated with hypertension, and poor com-
pliance. The latter is a complex and thoroughly explored
concept and challenge (e.g. [43]). Apparently, many
people with hypertension do not seem to recognize high
blood pressure as a progressive chronic illness, but ra-
ther misinterpret it as a risk factor in a gamble with a
potentially positive outcome [44,45].
Finally, the sex of the attending physician has been
shown to play a role in the quality of risk factor control
in patients with hypertension and dyslipidemia. In a
cross-sectional study by Journath et al., diabetic men
and women achieved goals for blood pressure control,
and men achieved goals for cholesterol control more
often if they were treated by female physicians [46].Likewise, a German study including 51,053 diabetes
patients treated by 3,096 physicians concluded that fe-
male physicians achieved a better quality of care than
their male counterparts, especially in risk management
important for future disease prognosis [47].
Differences between Europe and the United States/
Canada
Interestingly, there appears to be an intriguing difference
in hypertension prevalence and control, irrespective of
diabetes status, between Europe and the United States/
Canada that has not been appreciated and examined suffi-
ciently. Wolf-Maier et al. [48,49] compared sample sur-
veys conducted in the 1990s in Germany, Finland,
Sweden, England, Spain, Italy, Canada, and the United
States and found that even though mean BMI was very
similar across these countries, the prevalence of hyperten-
sion, defined as blood pressure > 140/90 mmHg or intake
of anti-hypertensive medication, differed remarkably. The
European average was 44.2% compared with 27.6% in
North America. Germany had the highest prevalence with
55.3% [48]. Treatment and control of hypertensive partici-
pants within the individual studies was also significantly
better in the United States than in Europe with 7.8%
hypertension control in the population (29.9% in treated
hypertensive participants) in Germany compared to 28.6%
(54.5% in treated hypertensives) in the United States [49].
In order to improve awareness, creative new approaches
have been successfully implemented in the United States,
e.g. by addressing the issue and counseling black men
during a visit at a barbershop [50]. Such innovative
ideas might also work in Germany – possibly for
younger men with diabetes and no previous cardiovas-
cular complications.
Conclusions
In the DIAB-CORE study, participants with diabetes
who were at the greatest odds of uncontrolled co-
morbidities and no pharmacotherapy were male,
younger, had lower BMI and no history of cardiovascular
disease. Although the general risk profile appears rela-
tively low, preventative efforts should not overlook, but
specifically consider this group of patients.
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